open access

Vol 45, No 2 (2011)
ARTYKUŁ ORYGINALNY
Submitted: 2010-06-12
Get Citation

Chlamydia pneumoniae seropositivity in Iranian patients with multiple sclerosis: a pilot study

Maryam Aghaei, Fereshteh Ashtari, Mohammadali Bahar, Mohammad Reza Falahian
DOI: 10.1016/S0028-3843(14)60023-2
·
Neurol Neurochir Pol 2011;45(2):128-131.

open access

Vol 45, No 2 (2011)
ARTYKUŁ ORYGINALNY
Submitted: 2010-06-12

Abstract

Background and purpose

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. Genetic and environmental factors could not completely explain the pathogenesis of the disease. Among environmental factors, infectious agents are of more interest than other candidates, so Chlamydia pneumoniae (C. pneumoniae) may have a role in MS development or progression. This study aimed to evaluate C. pneumoniae seropositivity in MS patients.

Material and methods

Serum samples obtained from a cohort of 85 patients with MS and from 50 age- and sex-matched controls were assessed for the presence of antibodies. IgM and IgG concentration for C. pneumoniae were determined with enzyme-linked immunosorbent assay (ELISA).

Results

The mean age was 33.8 (9.96) years in the MS group and 33.9 (10.7) years in controls. Female/male ratio was 3.5 : 1 in the MS group; 69 patients (81%) had relapsing-remitting course (RRMS) and 16 patients (19%) had secondary progressive course (SPMS). The median concentration of C. pneumoniae IgM in the MS group was 0.5 RU/mL (0.25–1) versus 0.5 RU/mL (0.3–0.8) in the control group (p = 0.66); likewise, the median concentration of C. pneumoniae IgG in MS patients was 57.3 RU/mL (17.05–95.1) compared with 56.15 RU/mL (6.85–102.5) in the control group (p = 0.85). Regarding the clinical course, C. pneumoniae IgG was 55.1 RU/mL (20.7–88.6) in RRMS and 59.1 RU/mL (5.35–112) in SPMS (p = 0.8).

Conclusion

No association was observed between MS and C. pneumoniae in Iranian MS patients.

Abstract

Background and purpose

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. Genetic and environmental factors could not completely explain the pathogenesis of the disease. Among environmental factors, infectious agents are of more interest than other candidates, so Chlamydia pneumoniae (C. pneumoniae) may have a role in MS development or progression. This study aimed to evaluate C. pneumoniae seropositivity in MS patients.

Material and methods

Serum samples obtained from a cohort of 85 patients with MS and from 50 age- and sex-matched controls were assessed for the presence of antibodies. IgM and IgG concentration for C. pneumoniae were determined with enzyme-linked immunosorbent assay (ELISA).

Results

The mean age was 33.8 (9.96) years in the MS group and 33.9 (10.7) years in controls. Female/male ratio was 3.5 : 1 in the MS group; 69 patients (81%) had relapsing-remitting course (RRMS) and 16 patients (19%) had secondary progressive course (SPMS). The median concentration of C. pneumoniae IgM in the MS group was 0.5 RU/mL (0.25–1) versus 0.5 RU/mL (0.3–0.8) in the control group (p = 0.66); likewise, the median concentration of C. pneumoniae IgG in MS patients was 57.3 RU/mL (17.05–95.1) compared with 56.15 RU/mL (6.85–102.5) in the control group (p = 0.85). Regarding the clinical course, C. pneumoniae IgG was 55.1 RU/mL (20.7–88.6) in RRMS and 59.1 RU/mL (5.35–112) in SPMS (p = 0.8).

Conclusion

No association was observed between MS and C. pneumoniae in Iranian MS patients.

Get Citation

Keywords

multiple sclerosis, Chlamydia pneumoniae, ELISA

About this article
Title

Chlamydia pneumoniae seropositivity in Iranian patients with multiple sclerosis: a pilot study

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 45, No 2 (2011)

Pages

128-131

DOI

10.1016/S0028-3843(14)60023-2

Bibliographic record

Neurol Neurochir Pol 2011;45(2):128-131.

Keywords

multiple sclerosis
Chlamydia pneumoniae
ELISA

Authors

Maryam Aghaei
Fereshteh Ashtari
Mohammadali Bahar
Mohammad Reza Falahian

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl